Prevagen class action claims supplement doesn’t improve memory

Prevagen class action lawsuit overview:

• Who: Plaintiff Donna Beatty is suing Quincy Bioscience Holding Co. Inc., Quincy Bioscience LLC, Prevagen Inc. and Quincy Bioscience Manufacturing LLC.
• Why: Beatty claims the companies misled consumers about the memory-improving benefits of its Prevagen dietary supplement.
• Where: The Prevagen class action lawsuit was filed in New York federal court.

A new Prevagen class action lawsuit accuses the company behind the dietary supplement of misleading consumers about its memory-improving benefits.

Plaintiff Donna Beatty filed the class action complaint against Quincy Bioscience Holding Co. Inc., Quincy Bioscience LLC, Prevagen Inc. and Quincy Bioscience Manufacturing LLC and Mark Underwood on Jan. 24 in New York federal court, alleging violations of state consumer laws.

According to the Prevagen class action lawsuit, Quincy Bioscience advertised that the Prevagen dietary supplement provides cognitive benefits such as healthy brain function, a sharper mind and clearer thinking.

Beatty claims a jury in New York found last year that Quincy Bioscience’s advertising for Prevagen has a tendency to deceive and that two of the advertising statements were materially misleading.

The only relief sought by the Federal Trade Commission in that case was injunctive relief, Beatty says.

She seeks to represent a New York class of consumers who purchased Prevagen. She asserts claims for violations of New York’s consumer protection laws and unjust enrichment and is seeking statutory damages on behalf of New York class members.

No scientific proof for advertised Prevagen benefits, class action alleges

According to the Prevagen class action lawsuit, Quincy Bioscience marketed the dietary supplement as providing cognitive benefits, but the product does not provide any of the advertised benefits.

Beatty claims Quincy Bioscience’s own expert admitted during the FTC trial that “not much of anything is shown to directly help improve healthy brain function, memory, and cognition.”

Further, Beatty alleges Quincy Bioscience has no studies showing that the active ingredient in Prevagen, apoaequorin, can cross the human blood-brain barrier and benefit cognition.

“Defendants’ own studies show that apoaequorin is rapidly digested in the stomach and broken down into amino acids and small peptides,” the Prevagen class action lawsuit says.

This is the most recent case in a string of class action lawsuits against Prevagen. Back in September 2020, Prevagen agreed to a class action settlement for similar allegations.

What do you think about the allegations made in this Prevagen class action lawsuit? Tell us your thoughts in the comments.

The plaintiffs are represented by Stacey Ann Van Malden of Goldberger & Dubin PC and Joel D. Smith and Yeremey O. Krivoshey of Smith Krivoshey PC.

The Prevagen class action lawsuit is Donna Beatty v. Quincy Bioscience Holding Co. Inc., et al., Case No. 1:25-cv-00727, in the U.S. District Court for the Southern District of New York.

Read About More Class Action Lawsuits & Class Action Settlements:

• Mielle Organics class action alleges false ‘Made in USA’ labeling
• Hershey consolidated class action claims candy wrappers contain unsafe PFAS levels
• Google agrees to $100M settlement to end AdWords class action
• Class action accuses Amazon of ‘greenwashing’ its paper products